EyeGene Inc. (KOSDAQ: 185490)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,250.00
-60.00 (-1.81%)
Sep 11, 2024, 12:25 PM KST
-14.92%
Market Cap 87.31B
Revenue (ttm) 2.84B
Net Income (ttm) -12.34B
Shares Out 27.03M
EPS (ttm) -504.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 75,129
Open 3,315.00
Previous Close 3,310.00
Day's Range 3,230.00 - 3,350.00
52-Week Range 2,430.00 - 4,895.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About EyeGene

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company’s products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculos... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 47
Stock Exchange KOSDAQ
Ticker Symbol 185490
Full Company Profile

Financial Performance

In 2023, EyeGene's revenue was 3.13 billion, a decrease of -40.96% compared to the previous year's 5.29 billion. Losses were -21.11 billion, -18.68% less than in 2022.

Financial Statements

News

There is no news available yet.